Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice.
The development of transgenic mouse models of amyotrophic lateral sclerosis (ALS) allows the testing of neuroprotective agents. We evaluated the effects of five agents in transgenic mice with the G93A Cu,Zn superoxide dismutase mutation. A novel inhibitor of poly(ADP-ribose) polymerase showed no effects on survival. Desmethylselegiline and CGP3466 are agents that exert antiapoptotic effects in vitro by preventing nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase. They had no significant effects on survival in the G93A mice. Trientine, a copper chelator, produced a modest significant increase in survival. Similarly administration of lipoic acid in the diet produced a significant improvement in survival. These results therefore provide evidence for potential therapeutic effects of copper chelators and lipoic acid in the treatment of ALS.
Andreassen
O A
OA
Neurochemistry Laboratory, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Dedeoglu
A
A
Friedlich
A
A
Ferrante
K L
KL
Hughes
D
D
Szabo
C
C
Beal
M F
MF
D000662:Amphetamines / Q000494:pharmacology* / Q000627:therapeutic use; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000235:genetics; D000818:Animals; D005260:Female; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009048:Motor Skills / Q000187:drug effects* / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D013534:Survival; D008063:Thioctic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D014266:Trientine / Q000494:pharmacology* / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects / Q000502:physiology
D000662:Amphetamines; D018696:Neuroprotective Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C017861:desmethylselegiline; D008063:Thioctic Acid; D014266:Trientine